| 2114 | Humans |
| 1150 | Animals |
| 563 | Female |
| 562 | Male |
| 524 | Coronavirus Infections (epidemiology) |
| 475 | Molecular Sequence Data |
| 470 | Coronavirus Infections (virology) |
| 435 | Base Sequence |
| 348 | Adult |
| 309 | Middle Aged |
| 279 | Mice |
| 273 | Amino Acid Sequence |
| 268 | Coronavirus Infections (transmission) |
| 252 | Middle East Respiratory Syndrome Coronavirus (genetics) |
| 251 | Coronavirus Infections (prevention & control) |
| 248 | Middle East Respiratory Syndrome Coronavirus (isolation & purification) |
| 238 | Algorithms |
| 223 | Aged |
| 216 | Coronavirus Infections (diagnosis) |
| 205 | Disease Outbreaks |
| 195 | Middle East Respiratory Syndrome Coronavirus |
| 188 | Models, Molecular |
| 186 | Protein Binding |
| 171 | Middle East Respiratory Syndrome Coronavirus (immunology) |
| 167 | Cell Line |
| 162 | Phylogeny |
| 151 | Binding Sites |
| 149 | Saudi Arabia (epidemiology) |
| 147 | Adolescent |
| 141 | Middle East Respiratory Syndrome Coronavirus (physiology) |
| 140 | Young Adult |
| 134 | Software |
| 134 | DNA (chemistry) |
| 130 | Coronavirus Infections (immunology) |
| 124 | Nucleic Acid Conformation |
| 122 | Kinetics |
| 121 | Sequence Analysis, DNA (methods) |
| 116 | Republic of Korea (epidemiology) |
| 115 | Sequence Analysis, DNA |
| 114 | Camelus (virology) |
| 113 | Coronavirus Infections (veterinary) |
| 112 | Child |
| 111 | Protein Conformation |
| 108 | Coronavirus Infections (drug therapy) |
| 103 | Middle East Respiratory Syndrome Coronavirus (pathogenicity) |
| 102 | Travel |
| 98 | Disease Models, Animal |
| 98 | Antibodies, Viral (blood) |
| 97 | Aged, 80 and over |
| 96 | Coronavirus (isolation & purification) |
| 94 | Genome, Viral |
| 91 | Viral Vaccines (immunology) |
| 91 | Antiviral Agents (pharmacology) |
| 90 | Coronavirus (genetics) |
| 88 | Antibodies, Viral (immunology) |
| 86 | Thermodynamics |
| 86 | Spike Glycoprotein, Coronavirus (genetics) |
| 86 | Computational Biology (methods) |
| 85 | Time Factors |
| 85 | Peptides (chemistry) |
| 81 | Retrospective Studies |
| 81 | Coronavirus Infections (pathology) |
| 80 | Child, Preschool |
| 78 | Coronavirus Infections (therapy) |
| 77 | Respiratory Tract Infections (virology) |
| 77 | Chlorocebus aethiops |
| 76 | Spike Glycoprotein, Coronavirus (immunology) |
| 76 | Computer Simulation |
| 76 | Chiroptera (virology) |
| 75 | Nucleic Acid Hybridization |
| 74 | Saudi Arabia |
| 73 | Structure-Activity Relationship |
| 73 | Oligonucleotides (chemistry) |
| 72 | Camelus |
| 71 | Risk Factors |
| 71 | Mutation |
| 71 | Evolution, Molecular |
| 70 | Vero Cells |
| 70 | Spike Glycoprotein, Coronavirus (metabolism) |
| 70 | Sequence Alignment |
| 70 | Escherichia coli (genetics) |
| 70 | Cells, Cultured |
| 70 | Antiviral Agents (therapeutic use) |
| 69 | Middle East Respiratory Syndrome Coronavirus (drug effects) |
| 69 | Mice, Inbred BALB C |
| 68 | Temperature |
| 68 | Antibodies, Neutralizing (immunology) |
| 66 | Sensitivity and Specificity |
| 66 | Respiratory Tract Infections (epidemiology) |
| 65 | Coronavirus Infections (mortality) |
| 63 | Global Health |
| 63 | Circular Dichroism |
| 62 | Zoonoses (virology) |
| 62 | Middle East (epidemiology) |
| 62 | Cross Infection (epidemiology) |
| 61 | Oligodeoxyribonucleotides (chemistry) |
| 61 | Dipeptidyl Peptidase 4 (metabolism) |
| 60 | Molecular Structure |
| 59 | RNA, Viral (genetics) |
| 59 | Cluster Analysis |
| 58 | Disease Reservoirs (virology) |
| 58 | Disease Outbreaks (prevention & control) |
| 57 | Virus Replication |
| 57 | Polymerase Chain Reaction |
| 57 | Models, Genetic |
| 56 | Real-Time Polymerase Chain Reaction |
| 56 | Enzyme-Linked Immunosorbent Assay |
| 56 | Electrophoresis, Polyacrylamide Gel |
| 56 | Crystallography, X-Ray |
| 55 | Severe Acute Respiratory Syndrome (virology) |
| 55 | Reproducibility of Results |
| 55 | Rats |
| 54 | Zoonoses (epidemiology) |
| 54 | Host-Pathogen Interactions |
| 54 | DNA (metabolism) |
| 53 | Virus Internalization |
| 53 | Middle East Respiratory Syndrome Coronavirus (classification) |
| 53 | Infant |
| 52 | Receptors, Virus (metabolism) |
| 52 | Models, Chemical |
| 51 | Treatment Outcome |
| 51 | Transcription Factors (metabolism) |
| 50 | Substrate Specificity |
| 50 | Hydrogen-Ion Concentration |
| 50 | Chromatography, High Pressure Liquid |
| 49 | Zoonoses (transmission) |
| 49 | RNA, Messenger (genetics) |
| 49 | Middle East |
| 49 | High-Throughput Nucleotide Sequencing |
| 49 | Genomics (methods) |
| 49 | Genome |
| 49 | DNA (genetics) |
| 48 | Severe Acute Respiratory Syndrome (epidemiology) |
| 48 | Sequence Homology, Amino Acid |
| 48 | Protein Structure, Tertiary |
| 48 | Cross-Sectional Studies |
| 48 | Antibodies, Neutralizing (blood) |
| 47 | Protein Structure, Secondary |
| 46 | Oligonucleotide Array Sequence Analysis (methods) |
| 46 | Molecular Weight |
| 46 | Infection Control (methods) |
| 46 | Coronavirus (physiology) |
| 45 | Reverse Transcriptase Polymerase Chain Reaction |
| 45 | Coronavirus (immunology) |
| 45 | Coronavirus (classification) |
| 45 | Communicable Diseases, Emerging (epidemiology) |
| 44 | Protein Multimerization |
| 44 | Peptides (immunology) |
| 44 | Lung (virology) |
| 43 | Viral Proteins (genetics) |
| 43 | Surveys and Questionnaires |
| 43 | SARS Virus (physiology) |
| 43 | SARS Virus (genetics) |
| 43 | Genetic Variation |
| 42 | Prevalence |
| 42 | HEK293 Cells |
| 42 | Cattle |
| 41 | Species Specificity |
| 41 | RNA (chemistry) |
| 41 | Dimerization |
| 41 | Computational Biology |
| 41 | Bacterial Proteins (metabolism) |
| 40 | Viral Proteins (metabolism) |
| 40 | Pneumonia, Viral (epidemiology) |
| 40 | Magnetic Resonance Imaging |
| 40 | Cross Infection (prevention & control) |
| 40 | Corpus Callosum (pathology) |
| 40 | Cloning, Molecular |
| 39 | Virus Replication (drug effects) |
| 39 | Viral Proteins (chemistry) |
| 39 | Transcription, Genetic |
| 39 | Spike Glycoprotein, Coronavirus (chemistry) |
| 39 | Pandemics |
| 39 | Models, Biological |
| 39 | Gene Expression |
| 39 | Epitopes (immunology) |
| 39 | DNA-Binding Proteins (metabolism) |
| 39 | Communicable Diseases, Emerging (virology) |
| 38 | Rabbits |
| 38 | Protein Folding |
| 38 | Promoter Regions, Genetic |
| 38 | Magnetic Resonance Spectroscopy |
| 38 | Dipeptidyl Peptidase 4 (genetics) |
| 38 | China |
| 37 | Mice, Inbred C57BL |
| 37 | Genome, Human |
| 37 | Databases, Genetic |
| 37 | DNA, Bacterial (genetics) |
| 37 | Cross Infection (transmission) |
| 37 | Cell Line, Tumor |
| 37 | Antibodies, Monoclonal (immunology) |
| 36 | T-Lymphocytes (immunology) |
| 36 | Models, Statistical |
| 36 | Coronavirus Infections (complications) |
| 35 | Seroepidemiologic Studies |
| 35 | Oligonucleotides, Antisense (pharmacology) |
| 35 | Oligodeoxyribonucleotides (chemical synthesis) |
| 35 | High-Throughput Nucleotide Sequencing (methods) |
| 35 | Base Composition |
| 34 | Population Surveillance |
| 34 | Neutralization Tests |
| 34 | Middle East Respiratory Syndrome Coronavirus (metabolism) |
| 34 | Ligands |
| 34 | DNA Replication |
| 34 | DNA Primers |
| 34 | Cricetinae |
| 34 | Coronavirus Infections (genetics) |
| 33 | World Health Organization |
| 33 | Syndrome |
| 33 | Recombinant Proteins (metabolism) |
| 33 | RNA, Messenger (metabolism) |
| 33 | Lung (pathology) |
| 32 | Viral Vaccines (genetics) |
| 32 | Oligonucleotides (genetics) |
| 32 | China (epidemiology) |
| 31 | Proteins (chemistry) |
| 31 | Peptides (metabolism) |
| 31 | Mutagenesis, Site-Directed |
| 31 | Health Personnel |
| 31 | Drug Design |
| 31 | Bacterial Proteins (genetics) |
| 30 | Viral Vaccines (administration & dosage) |
| 30 | Republic of Korea |
| 30 | Recombinant Proteins (chemistry) |
| 30 | Peptide Library |
| 30 | Nucleic Acid Denaturation |
| 30 | Molecular Conformation |
| 30 | In Vitro Techniques |
| 30 | Cross Infection (virology) |
| 30 | Blotting, Western |
| 29 | Zoonoses |
| 29 | Tumor Cells, Cultured |
| 29 | Sequence Alignment (methods) |
| 29 | Public Health |
| 29 | Middle East Respiratory Syndrome Coronavirus (chemistry) |
| 29 | Coronavirus (pathogenicity) |
| 29 | Communicable Diseases, Emerging (prevention & control) |
| 29 | Antiviral Agents (chemistry) |
| 28 | Sequence Homology, Nucleic Acid |
| 28 | Pneumonia, Viral (virology) |
| 28 | Pneumonia, Viral (transmission) |
| 28 | Influenza, Human (epidemiology) |
| 28 | Escherichia coli (metabolism) |
| 28 | Dose-Response Relationship, Drug |
| 28 | Disease Outbreaks (statistics & numerical data) |
| 27 | SARS Virus (pathogenicity) |
| 27 | Health Knowledge, Attitudes, Practice |
| 27 | Coronavirus Infections (blood) |
| 27 | Catalysis |
| 27 | Binding, Competitive |
| 26 | Vaccination |
| 26 | Severity of Illness Index |
| 26 | Risk Assessment |
| 26 | Respiratory Tract Infections (transmission) |
| 26 | RNA, Viral (metabolism) |
| 26 | Polymerase Chain Reaction (methods) |
| 26 | HeLa Cells |
| 26 | Genome, Bacterial |
| 26 | Gene Expression Regulation |
| 25 | Transfection |
| 25 | Stereoisomerism |
| 25 | SARS Virus (drug effects) |
| 25 | Recombination, Genetic |
| 25 | Plasmids |
| 25 | Oligonucleotides (chemical synthesis) |
| 25 | Oligodeoxyribonucleotides (metabolism) |
| 25 | Infant, Newborn |
| 25 | Incidence |
| 25 | Immunoglobulin G (blood) |
| 25 | Hot Temperature |
| 25 | DNA |
| 25 | Coronavirus Infections (metabolism) |
| 25 | Coronavirus (drug effects) |
| 25 | Chiroptera |
| 25 | Case-Control Studies |
| 25 | Alleles |
| 24 | Viral Load |
| 24 | United States |
| 24 | Solutions |
| 24 | SARS Virus (immunology) |
| 24 | Peptide Fragments (chemistry) |
| 24 | Oligonucleotide Array Sequence Analysis |
| 24 | Mice, Transgenic |
| 24 | Metagenomics (methods) |
| 24 | Macromolecular Substances |
| 24 | Infection Control |
| 24 | Immunohistochemistry |
| 24 | Immunoglobulin G (immunology) |
| 24 | Genotype |
| 24 | Gene Expression Profiling |
| 24 | Epitope Mapping |
| 24 | Disease Transmission, Infectious |
| 24 | Conserved Sequence |
| 24 | Betacoronavirus |
| 23 | Virus Shedding |
| 23 | Viral Nonstructural Proteins (metabolism) |
| 23 | Viral Nonstructural Proteins (genetics) |
| 23 | Severe Acute Respiratory Syndrome (transmission) |
| 23 | Recombinant Proteins (genetics) |
| 23 | RNA, Viral (analysis) |
| 23 | Protein Domains |
| 23 | Prognosis |
| 23 | Models, Theoretical |
| 23 | Middle East Respiratory Syndrome Coronavirus (enzymology) |
| 23 | Islam |
| 23 | Epitopes, T-Lymphocyte (immunology) |
| 23 | Disease Reservoirs |
| 23 | Contact Tracing |
| 23 | Betacoronavirus (genetics) |
| 23 | Bacterial Proteins (chemistry) |
| 22 | Spectrophotometry, Ultraviolet |
| 22 | Severe Acute Respiratory Syndrome (immunology) |
| 22 | Repetitive Sequences, Nucleic Acid |
| 22 | Receptors, Virus (genetics) |
| 22 | Protein Biosynthesis |
| 22 | Prospective Studies |
| 22 | Peptides (chemical synthesis) |
| 22 | Peptide Hydrolases (metabolism) |
| 22 | Influenza, Human (virology) |
| 22 | Communicable Diseases, Emerging (transmission) |
| 22 | Cell Membrane (metabolism) |
| 22 | Antigens, Viral (immunology) |
| 21 | Water (chemistry) |
| 21 | Virus Internalization (drug effects) |
| 21 | Severe Acute Respiratory Syndrome (drug therapy) |
| 21 | Serine Endopeptidases (metabolism) |
| 21 | Respiratory Tract Infections (diagnosis) |
| 21 | Proteolysis |
| 21 | Pandemics (prevention & control) |
| 21 | Macaca mulatta |
| 21 | Indicators and Reagents |
| 21 | Immunity, Innate |
| 21 | Genomics |
| 21 | Gene Library |
| 21 | Epidemiological Monitoring |
| 21 | Epidemics |
| 21 | DNA-Binding Proteins (genetics) |
| 21 | Corpus Callosum (diagnostic imaging) |
| 21 | Coronavirus Infections |
| 20 | Virus Diseases (virology) |
| 20 | Survival Analysis |
| 20 | Static Electricity |
| 20 | Severe Acute Respiratory Syndrome (prevention & control) |
| 20 | Sequence Analysis, RNA |
| 20 | Sequence Analysis, RNA (methods) |
| 20 | SARS Virus |
| 20 | Oxidation-Reduction |
| 20 | Oligodeoxyribonucleotides |
| 20 | Mass Spectrometry |
| 20 | Immunization |
| 20 | Hospitals |
| 20 | Genome, Viral (genetics) |
| 20 | Diagnosis, Differential |
| 20 | DNA, Single-Stranded (chemistry) |
| 20 | DNA Damage |
| 20 | DNA (analysis) |
| 20 | Cytokines (metabolism) |
| 20 | Bacteria (genetics) |
| 20 | Amino Acid Motifs |
| 19 | Viral Tropism |
| 19 | Vaccines, Synthetic (immunology) |
| 19 | Transcription Factors (genetics) |
| 19 | Tertiary Care Centers |
| 19 | Templates, Genetic |
| 19 | Spectrometry, Mass, Electrospray Ionization |
| 19 | Signal Transduction |
| 19 | Recombinant Proteins (immunology) |
| 19 | RNA (metabolism) |
| 19 | Protein Denaturation |
| 19 | Polymorphism, Single Nucleotide |
| 19 | Peptide Fragments (immunology) |
| 19 | Oligonucleotides (metabolism) |
| 19 | Oligonucleotide Probes |
| 19 | Internet |
| 19 | History, 21st Century |
| 19 | Genetic Vectors |
| 19 | Escherichia coli (enzymology) |
| 19 | Encephalitis (pathology) |
| 19 | Coronavirus |
| 19 | Chromatography, Gel |
| 18 | Viruses (genetics) |
| 18 | Virus Diseases (epidemiology) |
| 18 | Surface Properties |
| 18 | Respiratory System (virology) |
| 18 | RNA, Viral (isolation & purification) |
| 18 | RNA (genetics) |
| 18 | Pneumonia, Viral (prevention & control) |
| 18 | Peptides (pharmacology) |
| 18 | Open Reading Frames |
| 18 | Nucleotide Motifs |
| 18 | Host Specificity |
| 18 | Epitopes (chemistry) |
| 18 | Databases, Protein |
| 18 | Comorbidity |
| 18 | Cell Division (drug effects) |
| 17 | Virus Attachment |
| 17 | Viral Vaccines |
| 17 | United Arab Emirates (epidemiology) |
| 17 | Seasons |
| 17 | Protein Structure, Quaternary |
| 17 | Pregnancy |
| 17 | Pneumonia, Viral (diagnosis) |
| 17 | Peptide Fragments (metabolism) |
| 17 | Microscopy, Electron |
| 17 | Hydrogen Bonding |
| 17 | Genes, Viral |
| 17 | Drug Stability |
| 17 | Disease Reservoirs (veterinary) |
| 17 | DNA Repair |
| 17 | Consensus Sequence |
| 17 | Communicable Diseases, Emerging |
| 17 | Cohort Studies |
| 17 | CD4-Positive T-Lymphocytes (immunology) |
| 16 | Virulence |
| 16 | Transcription Factors (chemistry) |
| 16 | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization |
| 16 | Sequence Analysis, Protein (methods) |
| 16 | SARS Virus (enzymology) |
| 16 | Ribavirin (therapeutic use) |
| 16 | Respiratory Tract Infections (prevention & control) |
| 16 | RNA-Binding Proteins (metabolism) |
| 16 | Promoter Regions, Genetic (genetics) |
| 16 | Probability |
| 16 | Polymers (chemistry) |
| 16 | Osmolar Concentration |
| 16 | Oligopeptides (chemistry) |
| 16 | Metagenomics |
| 16 | Metagenome |
| 16 | Mass Spectrometry (methods) |
| 16 | Light |
| 16 | Immunity, Cellular |
| 16 | HIV-1 (immunology) |
| 16 | Cysteine Endopeptidases (chemistry) |
| 16 | Cell Survival (drug effects) |
| 16 | Binding Sites (genetics) |
| 16 | Bayes Theorem |
| 15 | Zoonoses (prevention & control) |
| 15 | Zoonoses (diagnosis) |
| 15 | United States (epidemiology) |
| 15 | Ultraviolet Rays |
| 15 | Support Vector Machine |
| 15 | Spectrometry, Fluorescence |
| 15 | Risk |
| 15 | Real-Time Polymerase Chain Reaction (methods) |
| 15 | Plasmids (genetics) |
| 15 | Oligosaccharides (chemistry) |
| 15 | Oligodeoxyribonucleotides (genetics) |
| 15 | Molecular Diagnostic Techniques (methods) |
| 15 | Lung (diagnostic imaging) |
| 15 | Influenza, Human (diagnosis) |
| 15 | Immune Evasion |
| 15 | Hydrolysis |
| 15 | Genes, Reporter |
| 15 | Escherichia coli Proteins |
| 15 | Epitopes |
| 15 | Encephalitis (etiology) |
| 15 | Encephalitis (diagnosis) |
| 15 | DNA Primers (genetics) |
| 15 | DNA Methylation |
| 15 | Cysteine Endopeptidases (metabolism) |
| 15 | Cross Reactions |
| 15 | Coronavirus Infections (psychology) |
| 15 | Coronaviridae (genetics) |
| 15 | Communicable Diseases, Emerging (diagnosis) |
| 15 | Communicable Disease Control |
| 15 | Chemical Phenomena |
| 15 | Catalytic Domain |
| 15 | CD8-Positive T-Lymphocytes (immunology) |
| 15 | Brain Diseases (pathology) |
| 15 | Base Pairing |
| 15 | Antibody Specificity |
| 14 | Viruses (isolation & purification) |
| 14 | Thionucleotides (pharmacology) |
| 14 | Severe Acute Respiratory Syndrome (pathology) |
| 14 | Sequence Analysis, Protein |
| 14 | Saccharomyces cerevisiae (genetics) |
| 14 | SARS Virus (isolation & purification) |
| 14 | Regulatory Sequences, Nucleic Acid |
| 14 | Receptors, Virus (chemistry) |
| 14 | Radiography |
| 14 | RNA, Small Interfering (genetics) |
| 14 | Pneumonia, Viral (drug therapy) |
| 14 | Phosphorylation |
| 14 | Peptide Nucleic Acids (chemistry) |
| 14 | Mutation (genetics) |
| 14 | Microscopy, Atomic Force |
| 14 | Inhibitory Concentration 50 |
| 14 | Health Personnel (statistics & numerical data) |
| 14 | Gene Expression Profiling (methods) |
| 14 | Fatal Outcome |
| 14 | Enzyme Inhibitors (pharmacology) |
| 14 | Electroencephalography |
| 14 | Disease Transmission, Infectious (prevention & control) |
| 14 | Databases, Nucleic Acid |
| 14 | DNA, Single-Stranded (metabolism) |
| 14 | DNA, Bacterial (analysis) |
| 14 | Coronavirus (metabolism) |
| 14 | Communicable Disease Control (methods) |
| 14 | Camelus (blood) |
| 14 | Biological Evolution |
